Rex Health Ventures

Rex Health Ventures, founded in 2012 and based in North Carolina, is a private equity firm focused on early-stage investments in healthcare and related technology companies. The firm is dedicated to discovering and developing innovative treatments, tools, products, and services that enhance the quality of healthcare. By investing in and partnering with entrepreneurs and companies, Rex Health Ventures aims to facilitate the entry of novel healthcare solutions into the marketplace. Their strategic initiatives include a comprehensive platform designed to support healthcare innovation, guiding promising startups from the initial idea phase through commercialization and expansion while addressing the unique challenges faced by early-stage ventures.

Bobby Helmedag

Managing Director

Anita Watkins

Managing Director

16 past transactions

Pryon

Funding Round in 2021
Pryon Inc. is an artificial intelligence company headquartered in Raleigh, North Carolina, that specializes in augmented intelligence solutions for enterprises. Founded in 2017, Pryon has developed a platform that enhances the capabilities of employees by facilitating access to knowledge and streamlining workflows. The platform intelligently orchestrates information across various channels and sources, utilizing advanced AI techniques such as natural language processing and context awareness. This enables organizations to navigate unstructured data more effectively, improve decision-making, and reduce operational complexities and costs. Through its innovative approach, Pryon aims to support businesses in their digital transformation efforts by making knowledge more accessible and actionable.

Pryon

Venture Round in 2021
Pryon Inc. is an artificial intelligence company headquartered in Raleigh, North Carolina, that specializes in augmented intelligence solutions for enterprises. Founded in 2017, Pryon has developed a platform that enhances the capabilities of employees by facilitating access to knowledge and streamlining workflows. The platform intelligently orchestrates information across various channels and sources, utilizing advanced AI techniques such as natural language processing and context awareness. This enables organizations to navigate unstructured data more effectively, improve decision-making, and reduce operational complexities and costs. Through its innovative approach, Pryon aims to support businesses in their digital transformation efforts by making knowledge more accessible and actionable.

BioStable

Series C in 2020
BioStable is a cardiovascular device company that develops innovative new products for the treatment of cardiovascular diseases. The company is led by an experienced group of industry executives with expertise in rapid and effective medical device development. The organization incorporates core strengths in all areas of product development including quality systems, design, engineering, prototyping and pilot production, in-vitro and in-vivo testing, manufacturing, global regulatory relationships, clinical product validation, market launch, and distribution. BioStable provides a competitive edge by minimizing time to market for cost-effective medical devices that deliver improved clinical outcomes. The company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to valve replacement for patients with aortic valve disease. BioStable was founded in

Bardy Diagnostics

Series B in 2019
Bardy Diagnostics, Inc. develops and manufactures cardiac monitoring devices. It offers Carnation Ambulatory Monitor (CAM), a cardiac patch monitor to capture low amplitude and frequency electrical signals that form the P-wave. The company also provides BDxCONNECT, a patient management system to the CAM patch, which offers a single system for creating, accessing, and managing patient CAM reports; and CAM reports that enables users to identify arrhythmia to aid clinical decision-making. Bardy Diagnostics, Inc. was incorporated in 2013 and is headquartered in Seattle, Washington. It has additional offices in Houston, Texas and New Providence, New Jersey.

Phynd Technologies

Series B in 2019
Since 2013, Phynd has been on a mission to simplify provider data management for healthcare systems. Phynd 360 is an innovative provider data management platform that serves as the central hub for your providers. Phynd optimizes provider data – people, places and services – for use in EHR, Marketing and Claims systems via platform tools which offer provider enrollment, management, outreach and search across the enterprise. Today, over 350 hospitals and 20,000+ locations across the U.S utilize the Phynd 360 Provider Platform to maintain a single, centralized hub of all provider data. For more information, visit www.Phynd.com.

Gauss Surgical

Series C in 2018
Gauss Surgical is a med-tech company that develops a vision-based platform for accurate and real-time measurement of surgical blood loss. They develop beautiful applications for iOS backed by sophisticated algorithms and a robust, HIPAA-compliant technical stack to enable real-time monitoring during surgery. The company was incorporated in 2011 and is headquartered in Menlo Park, California.

Emergo Therapeutics

Series A in 2018
Emergo Therapeutics is a pharmaceutical startup that develops treatment options for flu-like illnesses. It is focused on developing drugs to modulate inflammatory cytokines and improve the functioning of the immune system in various potential indications, starting with infectious diseases. Emergo’s therapeutic interventions are focused on reducing the production of inflammatory cytokines from mast cells. Emergo is headquartered in Durham, North Carolina.

Target PharmaSolutions

Series A in 2016
TARGET PharmaSolutions, Inc. specializes in providing real-world data (RWD) solutions that facilitate drug development and commercialization. Established in 2015 and headquartered in Durham, North Carolina, the company creates customized datasets and analyses to address healthcare evidence questions. It offers a comprehensive health evidence solution that aggregates RWD from a network of clinical sites, alongside bio specimen samples and consulting services. The foundation of TARGET PharmaSolutions was influenced by the HCV-TARGET project, which began in 2011 and demonstrated the effectiveness of their model in Hepatitis C research. The initiative has garnered significant support, influencing labels for sponsors and helping to avoid costly Phase IV commitments. The FDA has actively engaged with the HCV-TARGET project, reflecting its relevance in clinical analysis and healthcare outcomes.

Phononic

Series E in 2016
Phononic is a growth stage, semiconductor hardware company commercializing solid-state heat pumps and fully integrated systems that displace compressors, heat sinks, and fans for electronics cooling; residential and commercial refrigeration; and climate control. The company’s disruptive approach combines high-performance solid-state heat pumps integrated into a manufacturing-friendly systems architecture that realizes products that are smart, sustainable, and solid state-driven.

Bluesight

Series C in 2016
Bluesight is a software tool developed by Kit Check, Inc. that focuses on substance tracking and drug diversion detection within hospital pharmacies. This platform is part of a broader suite of cloud-based solutions designed to enhance the efficiency of pharmacy operations, including medication tracking and kit automation. Kit Check, Inc. utilizes Internet of Things (IoT) technology to significantly reduce kit replenishment time while increasing accuracy and minimizing errors. The company serves hospitals and pharmacies throughout the United States and Canada, tracking a substantial volume of medication, which contributes to improved supply chain management and operational safety. Founded in 2011 and based in Washington, D.C., Kit Check continues to innovate in the healthcare technology sector.

Arrivo BioVentures

Series A in 2016
Arrivo BioVentures LLC is a biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development of biologics and small molecules aimed at enhancing patient outcomes. Founded in 2015, the company focuses on drug development, leveraging its expertise to create reformulated products, new chemical entities, and biologics. Arrivo BioVentures emphasizes the importance of collaboration with regulatory bodies, such as the FDA, to streamline the approval process and efficiently execute clinical programs. By proactively engaging with regulators, the company seeks to minimize unexpected challenges and accelerate the implementation of its development programs.

Veran Medical Technologies

Venture Round in 2015
Veran Medical Technologies is an image-guided medical device company that helps physicians diagnose disease and deliver therapies. It develops a suite of products to enable physicians to diagnose disease and deliver therapies. It offers standards for minimally invasive delivery of interventional oncology therapies. The company provides plug-n-play delivery systems and navigated instruments. Its IG4 Platform allows clinicians to visualize various types of information integrated with a CT dataset, such as respiration, contrast-enhanced structures, PET, and ultrasound. The company also provides SPiN Drive System that acts as a GPS-like system to enable pulmonologists and surgeons to access peripheral solitary pulmonary nodules to diagnose malignancy. The company was incorporated in 2007 and is headquartered in St. Louis, Missouri.

Baebies

Venture Round in 2015
Baebies, Inc. specializes in manufacturing screening and pediatric testing equipment for newborns. The company produces SEEKER, a laboratory solution that simultaneously conducts multiple assays to quantitatively measure lysosomal enzyme activity from a single dried blood spot specimen. Additionally, Baebies offers FINDER, a near-patient testing device designed for pediatric applications. Serving hospitals and public health laboratories, Baebies aims to enhance newborn screening and pediatric testing through innovative technologies. Founded in 2014 by Richard West and Vamsee Pamula, the company has evolved from the successful development of digital microfluidics technology and the sale of Advanced Liquid Logic to Illumina. Based in Durham, North Carolina, Baebies focuses on improving health outcomes for children by introducing new tests and solutions for healthcare professionals and parents.

Baebies

Series A in 2015
Baebies, Inc. specializes in manufacturing screening and pediatric testing equipment for newborns. The company produces SEEKER, a laboratory solution that simultaneously conducts multiple assays to quantitatively measure lysosomal enzyme activity from a single dried blood spot specimen. Additionally, Baebies offers FINDER, a near-patient testing device designed for pediatric applications. Serving hospitals and public health laboratories, Baebies aims to enhance newborn screening and pediatric testing through innovative technologies. Founded in 2014 by Richard West and Vamsee Pamula, the company has evolved from the successful development of digital microfluidics technology and the sale of Advanced Liquid Logic to Illumina. Based in Durham, North Carolina, Baebies focuses on improving health outcomes for children by introducing new tests and solutions for healthcare professionals and parents.

Bluesight

Series B in 2015
Bluesight is a software tool developed by Kit Check, Inc. that focuses on substance tracking and drug diversion detection within hospital pharmacies. This platform is part of a broader suite of cloud-based solutions designed to enhance the efficiency of pharmacy operations, including medication tracking and kit automation. Kit Check, Inc. utilizes Internet of Things (IoT) technology to significantly reduce kit replenishment time while increasing accuracy and minimizing errors. The company serves hospitals and pharmacies throughout the United States and Canada, tracking a substantial volume of medication, which contributes to improved supply chain management and operational safety. Founded in 2011 and based in Washington, D.C., Kit Check continues to innovate in the healthcare technology sector.

Aerial BioPharma

Venture Round in 2012
Aerial BioPharma LLC is a biopharmaceutical company based in Morrisville, North Carolina, founded in 2011. The company specializes in drug development targeting conditions influenced by processes in the central nervous system. Aerial BioPharma is dedicated to creating both biologics and small molecules aimed at addressing various central nervous system disorders. Situated on the edge of Research Triangle Park, the company leverages its location to advance its research and development initiatives in this specialized field.